Microcirculatory effects of abciximab and eptifibatide: A critical appraisal

Journal of Invasive Cardiology

Volumn 15, Issue 9, 2003, Pages 481-483

  Kereiakes, Dean J ^a  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CD11B ANTIGEN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TROPONIN; VITRONECTIN;

ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; CORONARY ARTERY BLOOD FLOW; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG MECHANISM; DRUG RECEPTOR BINDING; EMBOLISM; ENZYME ACTIVITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; LEUKOCYTE MIGRATION; MICROCIRCULATION; MYOCARDIAL BLUSH GRADE; NOTE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; SCORING SYSTEM;

ACUTE DISEASE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY CIRCULATION; CORONARY THROMBOSIS; CORONARY VESSELS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MICROCIRCULATION; MYOCARDIAL ISCHEMIA; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STENTS; THROMBOEMBOLISM;

EID: 0141590215     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (19)

1. Roffi M, Mukherjee D, Chew DP, et al. Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: A pooled analysis of five randomized clinical trials, Circulation 2002;106:3063-3067.
2. Kerciakes DJ. Platelet glycoprotein IIb/IIIa inhibition and atheroembolism during bypass graft angioplasty - A cup half full (editorial). Circulation 2002;106:2994-2996.
3. Prati F, Pawlowski T, Gil R, et al. Srenting of culprit lesions in unstable angina leads to a marked reduction in plaque burden: A major role of plaque embolization? A serial intravascular ultrasound study. Circulation 2003;107:2320-2325.
4. Stoupakis G, Orlando J, Kalia H, et al. Perservation of myocardial microcirculation during mechanical reperfusion for myocardial ischemia with either abciximab or eptifibatide. J Invas Cardiol 2003;15:476-480.
5. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation: A randomised, placebo-controlled trial. Lancet 2000;356:2037-2044.
6. Kaul U, Gupta RK, Haridas KK, et al., Integrilin in Acute Myocardial Infarction (INAMI) Stenting Study Investigators. Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: A 30-day follow-up study. Cathet Cardiovasc Intervent 2002;57:497-503.
7. Stone GW, Grines CL, Cox DA, ct al., Controlled Abciximab and Devie Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966.
8. Wong GC, Morrow DA, Murphy S, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: A TACTICS-TIMI 18 substudy, Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 2002;106:202-207.
9. Hcnriques JP, Zijlstra F, van 't Hof AW, et al. Angiographic assessment of reperfusion in acute myocardial infarction by myocardial blush grade. Circulation 2003;107:2115-2119.
10. Kerciakes DJ, Runyon JP, Broderick TM, Shimshak TM. IIb's are not IIb's. Am J Cardiol. 2000;85:23C-31C.
11. Coller BS. Anti GP IIb/IIIa drugs: Current strategies and future directions.. Thromb Haemost 2001;86:427-443.
12. Palmerini T, Nedelman MA, Scudder LE, et al. Effects of abciximab on the acute pathology of blood vessels after arterial stenting in non-human primates. J Am Coll Cardiol 2002;40:360-366.
13. Furman MI, Kereiakes DJ, Krueger LA, et al. Leukocyte-platelet aggregation and platelet p-selectin and GP IIIa expression following percutancous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J 2001;142:790-798.
14. Thompson RD, Wakelin MW, Larbi KY, et al. Divergent effects of platelet-endothelial cell adhesion molecule-1 and beta 3 integrin blockade on leukocyte transmigration in vivo. J Immunol 2000;165:426-434.
15. Bishop GG, McPherson JA, Sanders JM, et al. Selective alpha(v)beta(3)-receptor blockade reduces macrophage infiltration and restenosis after balloon angioplasty in the atherosclerotic rabbit. Circulation 2001;103:1906-1911.
16. Barrabes JA, Garcia-Dorado D, Mirabct M, et al. Lack of effect of glycoprotcin IIb/IIIa blockade on myocardial platelet or polymorphonuclear leukocyte accumulation and on infarct size after transient coronary occlusion in pigs. Am Coll Cardiol 2002;39:157-165.
17. Neumann FJ, Blasini R, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary, flow and left ventricular function after the placement of coronary artery stents in acute myocardial infarction. Circ 1998;98:2695-2701
18. Aymong ED, Curtis MJ, Youssef M, et al. Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting. Circulation 2002;105:2981-2985.
19. Marzilli M, Sambuceti G, Testa R, Fedele S. Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina. J Am Coll Cardiol 2002;40:2102-2109.